Drug Trial Radar · NCT06052566
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Nov 21, 2023
Primary completion
Dec 5, 2024
Study completion Dec 5, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
Conditions
- Non-alcoholic Steatohepatitis
- Hepatic Impairment
Interventions
EfinopegdutideDrug
Subcutaneous injection administered at a dose of 7 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve From Time 0 to Infinity (AUC0-inf) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
- Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
- Maximum Plasma Concentration (Cmax) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
- Time to Maximum Concentration (Tmax) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
- Apparent Terminal Half-life (t/12) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
- Apparent Total Clearance (CL/F) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
- Apparent Volume of Distribution (Vz/F) of EfinopegdutideTime frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami ( Site 0005)
Miami, Florida
Advanced Pharma CR, LLC ( Site 0001)
Miami, Florida
Genesis Clinical Research, LLC ( Site 0006)
Tampa, Florida
American Research Corporation ( Site 0002)
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.